Masuo Yamaoka

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. ncbi Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
    J Steroid Biochem Mol Biol 129:115-28. 2012
  2. ncbi Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
    Masuo Yamaoka
    Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Clin Cancer Res 16:4319-24. 2010
  3. ncbi Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
    Tomohiro Kaku
    CNS Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd, Shonan Research Center, 26 1, Muraoka Higashi 2 chome, Fujisawa, Kanagawa 251 0012, Japan
    Bioorg Med Chem 19:6383-99. 2011
  4. ncbi Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
    Takahito Hara
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, Fujisawa, Japan
    J Steroid Biochem Mol Biol 134:80-91. 2013
  5. ncbi Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:2338-52. 2012
  6. ncbi Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1 Muraokahigashi 2 chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:422-34. 2012
  7. ncbi A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line
    Takahito Hara
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Cell Biol Int 34:177-84. 2010
  8. ncbi C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors
    Nobuyuki Matsunaga
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division Takeda Chemical Industries Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 12:4313-36. 2004
  9. ncbi Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Chemical Industries, Ltd, Osaka 532 8686, Japan
    Cancer Res 63:5622-8. 2003
  10. ncbi Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, Japan
    Prostate 65:268-75. 2005

Collaborators

  • Tomohiro Kaku
  • Masami Yamada
  • Takahito Hara
  • Satoshi Yamamoto
  • Masami Kusaka
  • Akihiro Tasaka
  • Jin Kouno
  • Nobuyuki Matsunaga
  • Naoyuki Kanzaki
  • Mitsuhiro Ito
  • Hideo Araki
  • Kazuyo Nakamura
  • Toshiyuki Takeuchi
  • Atsuo Baba
  • Tomohiko Suzaki
  • Takenori Hitaka
  • Kazumasa Hamamura
  • Atsushi Hasuoka
  • Shuichi Furuya
  • Takashi Santou
  • Naoki Tomita
  • Junichi Miyazaki
  • Yuri Suzuki
  • Kazutaka Ushio
  • Mayumi Nishiwaki
  • Masahiko Hattori
  • Yumi Imai
  • Yukiko Hikichi
  • Akio Ojida
  • Toshimasa Tanaka

Detail Information

Publications10

  1. ncbi Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
    J Steroid Biochem Mol Biol 129:115-28. 2012
    ..These findings suggest that orteronel may be an effective therapeutic option for diseases where androgen suppression is critical, such as androgen sensitive and CRPC...
  2. ncbi Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
    Masuo Yamaoka
    Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Clin Cancer Res 16:4319-24. 2010
    ..The study of circulating tumor cells will likely be important not only to identify patients likely to receive benefit from this therapeutic approach, but also to further understand the molecular mechanisms of resistance...
  3. ncbi Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
    Tomohiro Kaku
    CNS Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd, Shonan Research Center, 26 1, Muraoka Higashi 2 chome, Fujisawa, Kanagawa 251 0012, Japan
    Bioorg Med Chem 19:6383-99. 2011
    ..Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer...
  4. ncbi Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
    Takahito Hara
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, Fujisawa, Japan
    J Steroid Biochem Mol Biol 134:80-91. 2013
    ..Our data suggests that orteronel would therefore be effective for androgen-dependent disorders such as PC...
  5. ncbi Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:2338-52. 2012
    ..These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model...
  6. ncbi Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1 Muraokahigashi 2 chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:422-34. 2012
    ....
  7. ncbi A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line
    Takahito Hara
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Cell Biol Int 34:177-84. 2010
    ..These results suggest that an acquired mutation in beta-tubulin is associated with docetaxel resistance in PC and that a novel AR-targeted therapy is effective for docetaxel-resistant PC...
  8. ncbi C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors
    Nobuyuki Matsunaga
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division Takeda Chemical Industries Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 12:4313-36. 2004
    ..Furthermore, (S)-42 showed a potent suppression of testosterone biosynthesis after a single oral administration in monkeys. These data suggest that (S)-42 may be a promising agent for the treatment of androgen-dependent prostate cancer...
  9. ncbi Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Chemical Industries, Ltd, Osaka 532 8686, Japan
    Cancer Res 63:5622-8. 2003
    ....
  10. ncbi Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, Japan
    Prostate 65:268-75. 2005
    ..CONCLUSIONS: These results suggest the hypermutational state might occur in LNCaP-FGC cells during bicalutamide-treatment, which might create the W741C/L mutant AR leading to bicalutamide-resistance...